Yu YL, Chou RH, Liang JH, Chang WJ, Su KJ, Tseng YJ, Huang WC, Wang SC and Hung MC: Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides. PLoS One. 8:e613622013. View Article : Google Scholar : PubMed/NCBI

Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, et al: Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 30:1879–1787. 2012. View Article : Google Scholar : PubMed/NCBI

Ojo D, Wei F, Liu Y, Wang E, Zhang H, Lin X, Wong N, Bane A and Tang D: Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion. Curr Med Chem. 22:2360–2374. 2015. View Article : Google Scholar : PubMed/NCBI

Spring L, Bardia A and Modi S: Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: Rationale, current status, and future directions. Discov Med. 21:65–74. 2016.PubMed/NCBI

Lumachi F, Chiara GB, Foltran L and Basso SM: Proteomics as a guide for personalized adjuvant chemotherapy in patients with early breast cancer. Cancer Genomics Proteomics. 12:385–390. 2015.PubMed/NCBI

Williams CB, Soloff AC, Ethier SP and Yeh ES: Perspectives on epidermal growth factor receptor regulation in triple-negative breast cancer: Ligand-mediated mechanisms of receptor regulation and potential for clinical targeting. Adv Cancer Res. 127:253–281. 2015. View Article : Google Scholar : PubMed/NCBI

Hudis CA and Gianni L: Triple-negative breast cancer: An unmet medical need. Oncologist. 16:(Suppl 1). 1–11. 2011. View Article : Google Scholar : PubMed/NCBI

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI

Schofield RC, Ramanathan LV, Murata K, Fleisher M, Pessin MS and Carlow DC: Development of an assay for methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum by LC-MS/MS. Methods Mol Biol. 1383:213–222. 2016. View Article : Google Scholar : PubMed/NCBI

Hara A, Taguchi A, Aoki H, Hatano Y, Niwa M, Yamada Y and Kunisada T: Folate antagonist, methotrexate induces neuronal differentiation of human embryonic stem cells transplanted into nude mouse retina. Neurosci Lett. 477:138–143. 2010. View Article : Google Scholar : PubMed/NCBI

Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, Combe B, Flipo RM, Goupille P, Le Loët X, et al: Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 73:388–395. 2006. View Article : Google Scholar : PubMed/NCBI

Whittle SL and Hughes RA: Folate supplementation and methotrexate treatment in rheumatoid arthritis: A review. Rheumatology (Oxford). 43:267–271. 2004. View Article : Google Scholar : PubMed/NCBI

Cho KM, Kim YJ, Kim SH, Kim JW, Lee JO, Han JH, Lee KW, Kim JH, Kim CY, Bang SM, et al: Salvage treatment with intracerebrospinal fluid thiotepa in patients with leptomeningeal metastasis after failure of methotrexate-based treatment. Anticancer Res. 35:5631–5638. 2015.PubMed/NCBI

van der Plas E, Nieman BJ, Butcher DT, Hitzler JK, Weksberg R, Ito S and Schachar R: Neurocognitive late effects of chemotherapy in survivors of acute lymphoblastic leukemia: Focus on methotrexate. J Can Acad Child Adolesc Psychiatry. 24:25–32. 2015.PubMed/NCBI

Yiang GT, Chou PL, Hung YT, Chen JN, Chang WJ, Yu YL and Wei CW: Vitamin C enhances anticancer activity in methotrexate-treated Hep3B hepatocellular carcinoma cells. Oncol Rep. 32:1057–1063. 2014.PubMed/NCBI

Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, et al: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 43:972–980. 2013. View Article : Google Scholar : PubMed/NCBI

Takemura Y and Jackman AL: Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anticancer Drugs. 8:3–16. 1997. View Article : Google Scholar : PubMed/NCBI

Fukuda T, Tanabe M, Kobayashi K, Fukada I, Takahashi S, Iwase T and Ito Y: Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine. Springerplus. 4:3762015. View Article : Google Scholar : PubMed/NCBI

Leone JP, Leone J, Vallejo CT, Pérez JE, Romero AO, Machiavelli MR, Romero Acuña L, Domínguez ME, Langui M, Fasce HM, et al: Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience. Breast Cancer Res Treat. 143:313–323. 2014. View Article : Google Scholar : PubMed/NCBI

Wu CE, Chen SC, Lin YC, Lo YF, Hsueh S and Chang HK: Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy. Anticancer Res. 34:1301–1306. 2014.PubMed/NCBI

Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA and Tugwell P: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 41:1049–1060. 2014. View Article : Google Scholar : PubMed/NCBI

Lee HJ, Hong SK, Seo JK, Lee D and Sung HS: A case of cutaneous side effect of methotrexate mimicking Behçets disease. Ann Dermatol. 23:412–414. 2011. View Article : Google Scholar : PubMed/NCBI

Colomer Gallardo A, Martínez Rodríguez R, Castillo Pacheco C, González Satue C and Ibarz Servio L: Dermatological side effects of intravesical mitomycin C: Delayed hypersensitivity. Arch Esp Urol. 69:89–91. 2016.PubMed/NCBI

Elazzazy S, Mohamed AE and Gulied A: Cyclophosphamide-induced symptomatic hyponatremia, a rare but severe side effect: A case report. Onco Targets Ther. 7:1641–1645. 2014. View Article : Google Scholar : PubMed/NCBI

Sun W, Yan C, Jia S and Hu J: Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients. Int J Clin Exp Med. 7:5857–5861. 2014.PubMed/NCBI

Rietjens IM, Boersma MG, Haan L, Spenkelink B, Awad HM, Cnubben NH, van Zanden JJ, Woude H, Alink GM and Koeman JH: The pro-oxidant chemistry of the natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids. Environ Toxicol Pharmacol. 11:321–333. 2002. View Article : Google Scholar : PubMed/NCBI

Mason SA, Gatta PA Della, Snow RJ, Russell AP and Wadley GD: Ascorbic acid supplementation improves skeletal muscle oxidative stress and insulin sensitivity in people with type 2 diabetes: Findings of a randomized controlled study. Free Radic Biol Med. 93:227–238. 2016. View Article : Google Scholar : PubMed/NCBI

Lee WJ: The prospects of vitamin C in cancer therapy. Immune Netw. 9:147–152. 2009. View Article : Google Scholar : PubMed/NCBI

Nagappan A, Park KI, Park HS, Kim JA, Hong GE, Kang SR, Lee DH, Kim EH, Lee WS, Won CK, et al: Vitamin C induces apoptosis in AGS cells by down-regulation of 14-3-3σ via a mitochondrial dependent pathway. Food Chem. 135:1920–1928. 2012. View Article : Google Scholar : PubMed/NCBI

Guerriero E, Sorice A, Capone F, Napolitano V, Colonna G, Storti G, Castello G and Costantini S: Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines. PLoS One. 9:e1152872014. View Article : Google Scholar : PubMed/NCBI

Vetvicka V and Vetvickova J: Combination of glucan, resveratrol and vitamin C demonstrates strong anti-tumor potential. Anticancer Res. 32:81–87. 2012.PubMed/NCBI

Nagao T, Warnakulasuriya S, Nakamura T, Kato S, Yamamoto K, Fukano H, Suzuki K, Shimozato K and Hashimoto S: Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: A randomized controlled trial. Int J Cancer. 136:1708–1717. 2015. View Article : Google Scholar : PubMed/NCBI

Tokarski S, Rutkowski M, Godala M, Mejer A and Kowalski J: The impact of ascorbic acid on the concentrations of antioxidative vitamins in the plasma of patients with non-small cell lung cancer undergoing first-line chemotherapy. Pol Merkur Lekarski. 35:136–140. 2013.(In Polish). PubMed/NCBI

Nechuta S, Lu W, Chen Z, Zheng Y, Gu K, Cai H, Zheng W and Shu XO: Vitamin supplement use during breast cancer treatment and survival: A prospective cohort study. Cancer Epidemiol Biomarkers Prev. 20:262–271. 2011. View Article : Google Scholar : PubMed/NCBI

Subramani T, Yeap SK, Ho WY, Ho CL, Omar AR, Aziz SA, Rahman NM and Alitheen NB: Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen. J Cell Mol Med. 18:305–313. 2014. View Article : Google Scholar : PubMed/NCBI

Hong SW, Jin DH, Hahm ES, Yim SH, Lim JS, Kim KI, Yang Y, Lee SS, Kang JS, Lee WJ, et al: Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep. 18:811–815. 2007.PubMed/NCBI

Uetaki M, Tabata S, Nakasuka F, Soga T and Tomita M: Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. Sci Rep. 5:138962015. View Article : Google Scholar : PubMed/NCBI

van der Reest J and Gottlieb E: Anti-cancer effects of vitamin C revisited. Cell Res. 26:269–270. 2016. View Article : Google Scholar : PubMed/NCBI

Mense SM, Singh B, Remotti F, Liu X and Bhat HK: Vitamin C and alpha-naphthoflavone prevent estrogen-induced mammary tumors and decrease oxidative stress in female ACI rats. Carcinogenesis. 30:1202–1208. 2009. View Article : Google Scholar : PubMed/NCBI

Yiang GT, Yu YL, Lin KT, Chen JN, Chang WJ and Wei CW: Acetaminophen induces JNK/p38 signaling and activates the caspase-9-3-dependent cell death pathway in human mesenchymal stem cells. Int J Mol Med. 36:485–492. 2015.PubMed/NCBI

Yu YL, Yiang GT, Chou PL, Tseng HH, Wu TK, Hung YT, Lin PS, Lin SY, Liu HC, Chang WJ, et al: Dual role of acetaminophen in promoting hepatoma cell apoptosis and kidney fibroblast proliferation. Mol Med Rep. 9:2077–2084. 2014.PubMed/NCBI

Lin BR, Yu CJ, Chen WC, Lee HS, Chang HM, Lee YC, Chien CT and Chen CF: Green tea extract supplement reduces D-galactosamine-induced acute liver injury by inhibition of apoptotic and proinflammatory signaling. J Biomed Sci. 16:352009. View Article : Google Scholar : PubMed/NCBI

Kolli VK, Abraham P, Isaac B and Selvakumar D: Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy. 55:83–90. 2009. View Article : Google Scholar : PubMed/NCBI

Ohgidani M, Komizu Y, Goto K and Ueoka R: Residual powders from Shochu distillation remnants induce apoptosis in human hepatoma cells via the caspase-independent pathway. J Biosci Bioeng. 114:104–109. 2012. View Article : Google Scholar : PubMed/NCBI

Yu VW and Ho WS: Tetrandrine inhibits hepatocellular carcinoma cell growth through the caspase pathway and G2/M phase. Oncol Rep. 29:2205–2210. 2013.PubMed/NCBI

Wu Y, van der Schaft DW, Baaijens FP and Oomens CW: Cell death induced by mechanical compression on engineered muscle results from a gradual physiological mechanism. J Biomech. 49:1071–1077. 2016. View Article : Google Scholar : PubMed/NCBI

Chen J, Li Y, Hao H, Li C, Du Y, Hu Y, Li J, Liang Z, Li C, Liu J, et al: Mesenchymal stem cell conditioned medium promotes proliferation and migration of alveolar epithelial cells under Septic conditions in vitro via the JNK-P38 signaling pathway. Cell Physiol Biochem. 37:1830–1846. 2015. View Article : Google Scholar : PubMed/NCBI

Lee K, Chung YH, Ahn H, Kim H, Rho J and Jeong D: Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation. Int J Biol Sci. 12:235–245. 2016. View Article : Google Scholar : PubMed/NCBI

Tan CS, Gilligan D and Pacey S: Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 16:e447–e459. 2015. View Article : Google Scholar : PubMed/NCBI

Sato F, Kubota Y, Natsuizaka M, Maehara O, Hatanaka Y, Marukawa K, Terashita K, Suda G, Ohnishi S, Shimizu Y, et al: EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition. Cancer Biol Ther. 16:933–940. 2015. View Article : Google Scholar : PubMed/NCBI

Li X, Qin N, Wang J, Yang X, Zhang X, Lv J, Wu Y, Zhang H, Nong J and Zhang Q: Clinical observation of icotinib hydrochloride for advanced non-small cell lung cancer patients with EGFR status identified. Zhongguo Fei Ai Za Zhi. 18:734–739. 2015.(In Chinese). PubMed/NCBI

Osarogiagbon RU, Cappuzzo F, Ciuleanu T, Leon L and Klughammer B: Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: Results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Transl Lung Cancer Res. 4:465–474. 2015.PubMed/NCBI

Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, et al: Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: Clinical and biological activity. Clin Breast Cancer. 12:207–214. 2012. View Article : Google Scholar : PubMed/NCBI

Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, Vanderwal CA, Kirschbrown W, Holen KD and Rosen LS: Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 76:1025–1032. 2015. View Article : Google Scholar : PubMed/NCBI

Evans MK, Tovmasyan A, Batinic-Haberle I and Devi GR: Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. Free Radic Biol Med. 68:302–314. 2014. View Article : Google Scholar : PubMed/NCBI

Ohtani S, Iwamaru A, Deng W, Ueda K, Wu G, Jayachandran G, Kondo S, Atkinson EN, Minna JD, Roth JA, et al: Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Cancer Res. 67:6293–6303. 2007. View Article : Google Scholar : PubMed/NCBI

Lin SY, Lai WW, Chou CC, Kuo HM, Li TM, Chung JG and Yang JH: Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res. 16:509–519. 2006. View Article : Google Scholar : PubMed/NCBI

Nagao N, Nakayama T, Etoh T, Saiki I and Miwa N: Tumor invasion is inhibited by phosphorylated ascorbate via enrichment of intracellular vitamin C and decreasing of oxidative stress. J Cancer Res Clin Oncol. 126:511–518. 2000. View Article : Google Scholar : PubMed/NCBI

Liu JW, Nagao N, Kageyama K and Miwa N: Antimetastatic and anti-invasive ability of phospho-ascorbyl palmitate through intracellular ascorbate enrichment and the resultant antioxidant action. Oncol Res. 11:479–487. 1999.PubMed/NCBI

Pires AS, Marques CR, Encarnação JC, Abrantes AM, Mamede AC, Laranjo M, Gonçalves AC, Sarmento-Ribeiro AB and Botelho MF: Ascorbic acid and colon cancer: An oxidative stimulus to cell death depending on cell profile. Eur J Cell Biol. 95:208–218. 2016. View Article : Google Scholar : PubMed/NCBI

Beck R, Pedrosa RC, Dejeans N, Glorieux C, Levêque P, Gallez B, Taper H, Eeckhoudt S, Knoops L, Calderon PB, et al: Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. Invest New Drugs. 29:891–900. 2011. View Article : Google Scholar : PubMed/NCBI

Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, et al: Epigenetic impacts of ascorbate on human metastatic melanoma cells. Front Oncol. 4:2272014. View Article : Google Scholar : PubMed/NCBI

Ma Y, Chapman J, Levine M, Polireddy K, Drisko J and Chen Q: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 6:222ra182014. View Article : Google Scholar : PubMed/NCBI

Cieslak JA and Cullen JJ: Treatment of pancreatic cancer with pharmacological ascorbate. Curr Pharm Biotechnol. 16:759–770. 2015. View Article : Google Scholar : PubMed/NCBI

Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G and Ruberti G: MET gene amplification and MET receptor activation are not sufficient to predict efficacy of combined MET and EGFR inhibitors in EGFR TKI-resistant NSCLC cells. PLoS One. 10:e01433332015. View Article : Google Scholar : PubMed/NCBI

De S, Dermawan JK and Stark GR: EGF receptor uses SOS1 to drive constitutive activation of NF-κB in cancer cells. Proc Natl Acad Sci USA. 111:11721–11726. 2014. View Article : Google Scholar : PubMed/NCBI